Orphan Designation Requests To Get Slower US FDA Reviews
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has extended its deadline for delivering an orphan drug designation decision, placing more pressure on sponsors to ensure requests contain no problems from the start.
You may also be interested in...
Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
Stakeholders wonder about impact of placing orphan drug program staff "into review teams" as part of next iteration of user fee program.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.